JP2024511137A - Cd47およびpd-l1を標的とする二重特異性抗体ならびにその使用方法 - Google Patents
Cd47およびpd-l1を標的とする二重特異性抗体ならびにその使用方法 Download PDFInfo
- Publication number
- JP2024511137A JP2024511137A JP2023558578A JP2023558578A JP2024511137A JP 2024511137 A JP2024511137 A JP 2024511137A JP 2023558578 A JP2023558578 A JP 2023558578A JP 2023558578 A JP2023558578 A JP 2023558578A JP 2024511137 A JP2024511137 A JP 2024511137A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- acid sequence
- amino acid
- cdrl1
- cdrl2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163164329P | 2021-03-22 | 2021-03-22 | |
| US63/164,329 | 2021-03-22 | ||
| US202263317899P | 2022-03-08 | 2022-03-08 | |
| US63/317,899 | 2022-03-08 | ||
| PCT/EP2022/057555 WO2022200389A1 (en) | 2021-03-22 | 2022-03-22 | Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024511137A true JP2024511137A (ja) | 2024-03-12 |
| JP2024511137A5 JP2024511137A5 (cg-RX-API-DMAC7.html) | 2025-03-31 |
Family
ID=81384718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023558578A Pending JP2024511137A (ja) | 2021-03-22 | 2022-03-22 | Cd47およびpd-l1を標的とする二重特異性抗体ならびにその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12448444B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4314065A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024511137A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022245196A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3212056A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL305827A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022200389A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024512574A (ja) * | 2021-03-22 | 2024-03-19 | ノビミューン エスアー | Cd47およびpd-l1を標的とする二重特異性抗体ならびにその使用方法 |
| US12448444B2 (en) | 2021-03-22 | 2025-10-21 | Novimmune Sa | Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereof |
| WO2023174925A1 (en) | 2022-03-14 | 2023-09-21 | Novimmune Sa | Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells |
| EP4580755A1 (en) * | 2022-09-02 | 2025-07-09 | Novimmune S.A. | Reciprocally masked antibody-cytokine fusion proteins and methods of use thereof |
| AU2023362569A1 (en) * | 2022-10-21 | 2025-04-24 | Novimmune Sa | Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation |
| EP4574844A1 (en) * | 2023-12-22 | 2025-06-25 | Numab Therapeutics AG | Multispecific antibodies having specificity for cd47 and pdl1 |
| IL328540A (en) * | 2023-12-22 | 2026-07-01 | Numab Therapeutics AG | Antibody binding complexes specific for LILRB2 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018215835A1 (en) * | 2017-05-26 | 2018-11-29 | Novimmune Sa | Anti-cd47 x anti-mesothelin antibodies and methods of use thereof |
| WO2019016411A1 (en) * | 2017-07-21 | 2019-01-24 | Novimmune Sa | GENERATION OF MULTISPECIFIC ANTIBODY MIXTURES AND METHODS OF USE |
| JP2021505195A (ja) * | 2017-12-04 | 2021-02-18 | 北京韓美薬品有限公司Beijing Hanmi Pharm. Co., Ltd. | 天然抗体様構造を有し、ヘテロ二量体形態の抗pd−l1/抗cd47二重特異性抗体、ならびにその製造方法 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5030719A (en) | 1986-08-28 | 1991-07-09 | Teijin Limited | Cytotoxic antibody conjugates and a process for preparation thereof |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| EP0739904A1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
| ATE139900T1 (de) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| JPH10501681A (ja) | 1994-02-22 | 1998-02-17 | ダナ−ファーバー キャンサー インスティチュート | 核酸送達システムならびにその合成および使用方法 |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
| JP4958555B2 (ja) | 2004-09-22 | 2012-06-20 | 協和発酵キリン株式会社 | 安定化されたヒトIgG4抗体 |
| AU2010249470B2 (en) | 2009-05-20 | 2015-06-25 | Novimmune S.A. | Synthetic Polypeptide Libraries And Methods For Generating Naturally Diversified Polypeptide Variants |
| EP2513312B1 (en) | 2009-12-17 | 2015-03-18 | NovImmune SA | Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants |
| WO2012023053A2 (en) | 2010-08-16 | 2012-02-23 | Novimmune S.A. | Methods for the generation of multispecific and multivalent antibodies |
| CN105859889B (zh) | 2010-11-17 | 2020-01-07 | 中外制药株式会社 | 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子 |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| ES2767135T3 (es) | 2011-10-19 | 2020-06-16 | Novimmune Sa | Métodos para purificar anticuerpos |
| RU2693078C2 (ru) | 2012-12-03 | 2019-07-01 | Новиммун С.А. | Анти-cd47 антитела и способы их применения |
| US9111624B2 (en) | 2013-03-22 | 2015-08-18 | Katsuyuki Fujita | Semiconductor memory device |
| CN112566938B (zh) | 2018-06-03 | 2025-04-01 | 拉姆卡普生物测试有限公司 | 针对ceacam5和cd47的双特异性抗体 |
| US12448444B2 (en) | 2021-03-22 | 2025-10-21 | Novimmune Sa | Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereof |
| JP2024512574A (ja) | 2021-03-22 | 2024-03-19 | ノビミューン エスアー | Cd47およびpd-l1を標的とする二重特異性抗体ならびにその使用方法 |
| AU2023240346A1 (en) | 2022-03-24 | 2024-09-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
-
2022
- 2022-03-22 US US17/701,573 patent/US12448444B2/en active Active
- 2022-03-22 IL IL305827A patent/IL305827A/en unknown
- 2022-03-22 JP JP2023558578A patent/JP2024511137A/ja active Pending
- 2022-03-22 EP EP22718098.1A patent/EP4314065A1/en active Pending
- 2022-03-22 WO PCT/EP2022/057555 patent/WO2022200389A1/en not_active Ceased
- 2022-03-22 AU AU2022245196A patent/AU2022245196A1/en not_active Abandoned
- 2022-03-22 CA CA3212056A patent/CA3212056A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018215835A1 (en) * | 2017-05-26 | 2018-11-29 | Novimmune Sa | Anti-cd47 x anti-mesothelin antibodies and methods of use thereof |
| WO2019016411A1 (en) * | 2017-07-21 | 2019-01-24 | Novimmune Sa | GENERATION OF MULTISPECIFIC ANTIBODY MIXTURES AND METHODS OF USE |
| JP2021505195A (ja) * | 2017-12-04 | 2021-02-18 | 北京韓美薬品有限公司Beijing Hanmi Pharm. Co., Ltd. | 天然抗体様構造を有し、ヘテロ二量体形態の抗pd−l1/抗cd47二重特異性抗体、ならびにその製造方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022245196A1 (en) | 2023-09-21 |
| CA3212056A1 (en) | 2022-09-29 |
| EP4314065A1 (en) | 2024-02-07 |
| WO2022200389A1 (en) | 2022-09-29 |
| US12448444B2 (en) | 2025-10-21 |
| IL305827A (en) | 2023-11-01 |
| US20220315655A1 (en) | 2022-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240400720A1 (en) | Anti-cd47 antibodies and methods of use thereof | |
| JP7220161B2 (ja) | 抗CD47x抗メソテリン抗体およびそれを使用する方法 | |
| US12448444B2 (en) | Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereof | |
| JP2020526478A6 (ja) | 抗CD47x抗メソテリン抗体およびそれを使用する方法 | |
| US12583922B2 (en) | Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereof | |
| US20180142018A1 (en) | Anti-cd19 antibodies and methods of use thereof | |
| CN111201031B (zh) | 抗CD47 x抗间皮素抗体及其使用方法 | |
| CN120476144A (zh) | 用于免疫检查点依赖性T细胞活化的PD-L1xCD28双特异性抗体 | |
| CN117412992A (zh) | 靶向cd47和pd-l1的双特异性抗体及其使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231215 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250321 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250321 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260106 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20260626 |